Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVolex Regulatory News (VLX)

Share Price Information for Volex (VLX)

Share Price is delayed by 15 minutes
Get Live Data
505.00    8.00 (1.61%)
Bid:
509.00
Ask:
511.00
Spread: 2.00 (0.393%)
Market Cap: £930.58m
VLX Live PriceLast checked at - London Stock Exchange

Intraday Volex Share Chart

Update on Move to the Main Market

25 Jun 2026 07:00

RNS Number : 6499J
Volex PLC
25 June 2026
 

THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN VOLEX PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

 

LEI: 213800HBLQNH5FXXGE63

25 June 2026

Volex plc

("Volex", the "Company", or the "Group")

Update on Move to the Main Market

 

Volex plc (AIM: VLX), the specialist integrated manufacturer of critical power and data transmission products, today provides an update in relation to the proposed admission of its ordinary shares ("Ordinary Shares") to the equity shares (commercial companies) category of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange ("Admission").

 

Further to its announcement on 7 April 2026, the Company expects that (i) Admission will take place at 8.00 a.m. on 24 July 2026; and (ii) the Ordinary Shares will be cancelled from trading on AIM concurrently at 8.00 a.m. on 24 July 2026. Accordingly, and pursuant to Rule 41 of the AIM Rules for Companies, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on AIM. The last day of trading in the Company's Ordinary Shares on AIM is expected to be 23 July 2026.

 

Admission will be effected through an introduction of the Company's existing Ordinary Shares and the Company is not offering any new Ordinary Shares nor any other securities in connection with Admission.

 

Admission remains subject to a number of conditions, including the approval by the Financial Conduct Authority of a prospectus and admission by the London Stock Exchange of the Ordinary Shares to trading on the Main Market. Admission is not conditional upon shareholder approval.

 

Shareholders should note that the Company's shares will no longer be traded on AIM with effect from Admission and should take their own financial and taxation advice regarding the consequences of Admission including with respect to their personal tax position.

 

-ENDS-

 

For further information please contact:

 

Volex plc

+44 (0) 1256 442570

Nat Rothschild, Chief Executive Officer

investor.relations@volex.com

Jon Boaden, Chief Financial Officer

Peel Hunt LLP - Sponsor, Nominated Adviser & Joint Broker

+44 (0) 20 7418 8900

Ed Allsopp

Dom Convey

Asha Chotai

Tom Graham

Jefferies - Joint Broker

+44 (0) 20 7029 8000

Philip Noblet

Sam Barnett

Harry Le May

Sodali & Co. - Media Enquiries

+44 (0) 20 7250 1446

James White

Nicholas Johnson

 

About Volex plc

Volex plc (AIM:VLX) is a driving force in integrated manufacturing for mission-critical applications and a global leader in power and data connectivity solutions. Our diverse operations support international blue-chip customers in five key end-markets: EV & Electrification, Consumer Electricals, Medical, Complex Industrial Technology and Off-Highway. Headquartered in the UK, we orchestrate operations across 23 advanced manufacturing facilities, uniting approximately 12,500 dynamic individuals across 25 countries. Our extraordinary products find their way to market through our localised sales teams and authorised distributor partners, supporting Original Equipment Manufacturers and Electronic Manufacturing Services companies across the globe. In a world that grows more digitally complex by the day, customers trust us to deliver power and connectivity that drives everything from household essentials to life-saving medical equipment. Learn more at www.volex.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURSEAFMLEMSEIM
Date   Source Headline
25th Jun 20267:00 amRNSPreliminary Group Results FY2026
25th Jun 20267:00 amRNSUpdate on Move to the Main Market
26th May 20263:00 pmRNSNotice of Results
15th May 20267:45 amRNSHolding(s) in Company
11th May 20267:00 amRNSHolding(s) in Company
30th Apr 20263:07 pmRNSHolding(s) in Company
22nd Apr 20267:00 amRNSCapital Markets Event
7th Apr 20267:00 amRNSLaunch of £40 million Share Buyback Programme
7th Apr 20267:00 amRNSUpdate on Move to the Main Market
26th Mar 20265:30 pmRNSHolding(s) in Company
25th Mar 20267:00 amRNSTrading update and Notice of Capital Markets Event
20th Mar 20262:00 pmRNSDirector/PDMR Shareholding
10th Feb 20267:45 amRNSHolding(s) in Company
2nd Feb 20264:45 pmRNSDirector/PDMR Shareholding
30th Jan 20264:30 pmRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSTrading Update
12th Jan 20265:30 pmRNSDirector/PDMR Shareholding
8th Jan 20262:00 pmRNSDirector/PDMR Shareholding
5th Jan 20263:00 pmRNSIssue of Equity and Total Voting Rights
15th Dec 20257:00 amRNSDirector/PDMR Shareholding
11th Dec 20255:55 pmRNSDirector/PDMR Shareholding
4th Dec 202511:30 amRNSScrip Reference Price
12th Nov 20257:00 amRNSAppointment of Non-Executive Chair and CEO
12th Nov 20257:00 amRNSHalf-year Report
20th Oct 20257:00 amRNSNotice of Results
16th Oct 20257:00 amRNSHalf Year Trading Update
29th Sep 20251:25 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSHolding(s) in Company
15th Sep 202511:30 amRNSDirector/PDMR Shareholding
15th Sep 202510:15 amRNSHolding(s) in Company
5th Sep 20259:00 amRNSDirector/PDMR Shareholding
1st Sep 20251:00 pmRNSIssue of Equity and Total Voting Rights
7th Aug 20254:35 pmRNSResult of AGM
7th Aug 202512:30 pmRNSScrip Reference Price
7th Aug 20257:00 amRNSAGM Statement
4th Aug 20252:00 pmRNSHolding(s) in Company
7th Jul 20254:35 pmRNSPDMR / PCA Shareholding
4th Jul 202511:00 amRNSNotice of AGM and Publication of Annual Report
26th Jun 20257:00 amRNSPreliminary Group Results FY2025
2nd Jun 20257:00 amRNSNotice of Results and Investor Presentation
16th Apr 20252:00 pmRNSDirector/PDMR Shareholding
16th Apr 20251:00 pmRNSDirector/PDMR Shareholding
10th Apr 20256:00 pmRNSDirector/PDMR Shareholding
7th Apr 20257:00 amRNSFull Year Trading Update
19th Mar 20253:30 pmRNSDirector/PDMR Shareholding
13th Mar 20255:45 pmRNSHolding(s) in Company
27th Jan 20257:00 amRNSChange of Adviser
27th Jan 20257:00 amRNSTrading Update
16th Jan 20251:15 pmRNSDirector/PDMR Shareholding
16th Jan 20251:15 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.